Cantargia receives positive EMA opinion for orphan designation of nadunolimab in pancreatic cancer.

NORDIC BUSINESS REPORT-October 14, 2021-Cantargia receives positive EMA opinion for orphan designation of nadunolimab in pancreatic cancer

(C)2021 M2 COMMUNICATIONS http://www.m2.com

Swedish biotechnology company Cantargia AB (STO:CANTA) announced on Thursday a positive opinion from European authorities for orphan designation of nadunolimab (CAN04) for treatment of pancreatic cancer.

The positive opinion from the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) was based on data from the ongoing CANFOUR trial, a phase I/IIa study in which CAN04 is being investigated in patients with advanced pancreatic ductal adenocarcinoma (PDAC) as first-line combination with gemcitabine and nab-paclitaxel.

The European Commission is now expected to grant the orphan...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT